Coronary inflammation: measuring the artery, not just the blood
Eric Topol has written on why two large cardiovascular outcome trials came up empty this year — ZEUS, testing the interleukin-6 antibody ziltivekimab, and Lp(a)HORIZON, testing pelacarsen. Both selected and…
